Substance / Medication

Olopatadine hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Atopic conjunctivitis

Allergic conjunctivitis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis.

Ayyappanavar Shruti, Sridhar Sriya, Kumar Kiran et al. · Indian J Ophthalmol · 2021

PMID: 33463568RCTFull text (PMC)

Pupil Diameter, Corneal Thickness, and Anterior Chamber Alterations Following Topical Olopatadine Hydrochloride 0.1%: A Single-Masked Randomized Controlled Clinical Study.

Çavdarli Cemal, Topcu Yilmaz Pınar · J Ocul Pharmacol Ther · 2020

PMID: 32250190RCT

Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study.

Liu Rui-Fen, Wu Xiao-Xuan, Wang Xiao et al. · Int Forum Allergy Rhinol · 2017

PMID: 27869354RCTFull text (PMC)

Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits.

Iyer Ganesh R, Cason Marita M, Womble Scott W et al. · J Ocul Pharmacol Ther · 2015

PMID: 25775192Observational

Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis.

Mortemousque B, Bourcier T, Khairallah M et al. · J Fr Ophtalmol · 2014

PMID: 24388379Observational

Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis.

Okubo Kimihiro, Okuda Minoru, Magara Hiroshi et al. · Curr Med Res Opin · 2010

PMID: 20443650Observational

Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis.

Kamis Umit, Ozturk Banu T, Ozkagnici Ahmet et al. · Acta Ophthalmol Scand · 2006

PMID: 16445458Observational

The effects of olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice.

Tamura Tadafumi, Amano Toru, Ohmori Kenji et al. · Eur J Pharmacol · 2005

PMID: 16259975Observational

Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis.

Meltzer Eli O, Hampel Frank C, Ratner Paul H et al. · Ann Allergy Asthma Immunol · 2005

PMID: 16400902Observational

Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar.

Ratner Paul H, Hampel Frank C, Amar Niran J et al. · Ann Allergy Asthma Immunol · 2005

PMID: 16312171Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Olopatadine hydrochloride (substance)
SNOMED CT: 108843008
UMLS CUI: C0771892

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.